We are now moving to phase 2 of the course on Gases and Vapors – and this is principally directed to anesthesiologists.

General anesthesia is not simply unconsciousness; it requires hypnosis, amnesia, immobility, autonomic stability, and analgesia.
There is no universally agreed quantitative definition of anesthetic depth; practical clinical endpoints guide real-world anesthesia.
Ether ushered in modern anesthesia but was limited by high blood and tissue solubility and flammability, leading to slow induction and emergence.
Safety concerns, particularly flammability, led to the abandonment of agents such as cyclopropane despite favorable pharmacology.
Methoxyflurane represented a major advance but fell out of routine use due to extensive metabolism and fluoride-related toxicity.
Progressive halogenation of ether derivatives produced agents with greater stability, lower solubility, and reduced metabolism.
Isoflurane marked a major milestone due to its minimal metabolism and predictable pharmacology.
Desflurane offers extremely rapid onset and emergence but is limited by pungency and airway irritation.
Sevoflurane became dominant primarily because it is non-pungent and universally applicable, allowing inhalational induction and use across all patient groups.
Nitrous oxide historically reduced volatile requirements in high-flow systems but is less essential in modern low-flow anesthesia.
Understanding volatile anesthetics requires grasping blood–gas solubility, lipid solubility, tissue uptake, and their effects on onset, potency, and emergence.

These principles set the foundation for understanding MAC, its utility, and its limitations.